5 FDA drug approvals to watch in 2026

Potential blockbusters and root-cause treatments from Eli Lilly, Merck, Takeda and others could get a regulatory nod this year.

By Alexandra Pecci • Jan. 7, 2026

PharmaVoice’s Crystal Ball: Market and policy forces shaping the industry

How pharma leaders believe the regulatory and investment market landscape will change in 2026. 

By Meagan Parrish • Jan. 6, 2026

Explore the Trendline➔

Oncology R&D

Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.   

By PharmaVoice staff

3 of China’s most innovative pharma companies

The top Chinese drugmakers succeeding in both innovation and business savvy.

By Kelly Bilodeau • Jan. 5, 2026

Biogen’s CIO is betting on a tech and AI overhaul to ‘pave the highways’ toward growth

Guy Hadari discusses how his role has changed with the introduction of new technologies, and what that means for Biogen’s future.

By Michael Gibney • Dec. 19, 2025

The leading GLP-1 contenders in pharma’s race for an obesity pill

Recent mid-stage readouts reveal how the market for an oral weight loss drug could take shape. 

By Alivia Kaylor • Dec. 18, 2025

3 key takeaways from the FDA’s new animal testing guidance

The agency’s moves to end animal testing are “not a fluke.” Here’s what drugmakers need to know about where it goes from here.

By Alexandra Pecci • Dec. 17, 2025

After years of debate, the Biosecure Act could be headed for Trump’s desk

The revised version of the bill softens compliance burdens between U.S. pharma firms and Chinese suppliers, but still has teeth.

By Kelly Bilodeau • Dec. 15, 2025

Amylyx pins its next hopes on a niche drug in the obesity space

A lot is riding on Amylyx’s late-stage candidate for post-bariatric hypoglycemia.

By Meagan Parrish • Dec. 12, 2025

Pharma’s top deals in 2025

The year’s three largest acquisitions signal where pharma is willing to pay big for promising candidates.

By Michael Gibney • Dec. 11, 2025

Will 2026 be pharma’s M&A breakout year?

Big Pharma needs new products to replenish pipelines and has plenty of money in the coffers, but looming uncertainties could stymie dealmaking again.

By Kelly Bilodeau • Dec. 10, 2025

How Lilly uses Big Pharma heft to lift up-and-coming biotechs

With great power comes great responsibility, and Eli Lilly is employing financial success and technical know-how to give smaller biotechs a leg up.

By Michael Gibney • Dec. 9, 2025

Along with NIH cuts come risks to patient safety and scientific data

The abrupt withdrawal of research funds affected 74,000 clinical trial participants, including some already taking the drugs being studied.

By Kelly Bilodeau • Nov. 26, 2025

What’s next in the eye disease pipeline?

An early gene therapy breakthrough spurred investments, but can the industry maintain momentum?  

By Kelly Bilodeau • Nov. 24, 2025

Amylin could reign supreme in the next wave of obesity drugs

With investment in amylin analogs on the rise for weight management, three key candidates are inching closer to critical readouts.

By Alivia Kaylor • Nov. 18, 2025

The next leap in Alzheimer’s R&D is coming, but not around the corner

While a couple drugs have reached the market, their effects are still modest, and experts say a true paradigm shift is still a ways off.

By Kelly Bilodeau • Nov. 17, 2025

RNAi looked doomed to fail — until Alnylam’s science chief found a way

Kevin Fitzgerald, Alnylam Pharmaceuticals’ chief scientific officer, reveals the hard times that led to RNAi success, and what it takes to pave new roads in biotech.

By Michael Gibney • Nov. 13, 2025

Why Pfizer and Novo are duking it out over weight loss startup Metsera

A brutal bidding war between two industry giants over a clinical-stage drugmaker is a sign of the weight loss arena’s high stakes.

By Michael Gibney • Nov. 6, 2025

Chinese drugmaker becomes top trial sponsor — and other clinical trends

The industry’s top indication areas for R&D and other shifts in the clinical trial landscape last year.

By Kelly Bilodeau • Nov. 5, 2025

Imunon’s non-viral DNA candidate may have cracked the code in frontline ovarian cancer

Imunon is showing off promising phase 3 data at a gynecologic cancer conference this week.

By Alexandra Pecci • Nov. 5, 2025

Biogen’s yearslong lupus R&D journey could soon pay off

Following a lengthy R&D process, two new molecules from Biogen could add much-needed treatments for a disease that’s been difficult to pin down.

By Michael Gibney • Nov. 4, 2025

Roche taps an AI specialist to craft new brain drugs

For $55 million, Roche gains access to Manifold Bio’s drug discovery technology, which will be used to develop new “shuttles” that can get medicines across the blood-brain barrier.

By Jacob Bell • Nov. 4, 2025

One of the few late-stage ALS contenders hits a critical juncture

MediciNova has launched a potentially pivotal trial for what it hopes is a disease-modifying ALS drug.

By Meagan Parrish • Oct. 31, 2025

Corporate venture firms stepped in for drug startups during biotech funding pullback

According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have been among the most active investors in biotech startups this year.

By Gwendolyn Wu • Oct. 31, 2025

Novartis’ $12B Avidity deal shows a willingness to take big swings in neuroscience

A premium paid for RNA candidates reflects what the pharma giant has sought to do for the last few years: aim at revolutionary technology that fits into their own expertise.

By Michael Gibney • Oct. 28, 2025

Takeda stakes more than $11B on cancer drugs from China

The Japanese pharma is licensing up to three next-generation cancer drugs from Innovent Biologics in a deal it believes to be “transformative” for its oncology portfolio.

By Ben Fidler • Oct. 24, 2025